CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally
Additionally, investors may have begun repositioning portfolios ahead of the release of second-quarter earnings results.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 10,165,400 | $345,928,566 | +14% | 3.46% |
| 2. | Orbis Investment Management William B. Gray | 1,562,932 | $53,186,576 | +6% | 0.3% |
| 3. | EcoR1 Capital Oleg Nodelman | 1,389,276 | $47,277,062 | 2.8% | |
| 4. | SR One Capital Simeon George | 1,048,951 | $35,695,803 | 9.17% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 797,200 | $27,128,716 | +841% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.85 | 7,000 | $313,947.90 | 7,000 | 2025-02-26 | Filing | |
| $24.95 | 27,461 | $685,116.25 | 5,380,940 | 2018-12-27 | Filing | |
| $24.89 | 12,737 | $317,077.43 | 5,353,479 | 2018-12-26 | Filing | |
| $24.97 | 53,655 | $1,339,695.60 | 5,340,742 | 2018-12-24 | Filing | |
| $23.18 | 11,742 | $272,139.64 | 5,287,087 | 2018-12-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.94 | 3,932 | $141,316.08 | 6,068 | 2025-05-29 | Filing | |
| $41.23 | 10,031 | $413,578.13 | 195,085 | 2025-03-21 | Filing | |
| $41.23 | 1,714 | $70,668.22 | 10,544 | 2025-03-21 | Filing | |
| $41.23 | 2,197 | $90,582.31 | 16,767 | 2025-03-21 | Filing | |
| $41.23 | 3,185 | $131,317.55 | 81,729 | 2025-03-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 82,607 | $4,309,607 | 0.01% | |
| 2. | 24,700 | $1,201,408 | 0.97% | |
| 3. | 20,310 | $987,878 | 0.69% | |
| 4. | 18,555 | $902,515 | 0.01% | |
| 5. | 2,950 | $143,488 | 0.01% |
News See All
H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s supplemental update to its Phase 1 CTX310 trial findings, H.C.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will summarize the bulls’ thesis on CRSP.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this article, we will summarize the bulls’ thesis on CRSP.
12 Most Shorted Stocks in 2025
Reuters reported that President Trump’s tariffs have impacted the broader stock markets, weighing on investors’ sentiments, as worries related to the economic slowdown drove a market sell-off which...
Ark Invest Stock Portfolio: Top 10 Stocks to Buy
ARK Investment Management LLC, commonly known as ARK Invest, is an American investment management firm headquartered in St. Petersburg, Florida.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
Billionaire Hedge Funds
